President Trump sure has ironic timing. On Sunday Gilead Sciences announced a $21 billion offer to buy Immunomedics, which recently launched a breakthrough therapy for hard-to-treat metastatic breast cancer. Hours later Mr. Trump signed an executive order that could make other life-saving therapies less likely.
